Option Care Health, Inc. (OPCH) Stock Price & How to Invest
Last updated July 2026
Short answer
OPCH is Option Care Health, the largest independent home and alternate-site infusion therapy provider in the US, and it trades as a steady, cash-generative healthcare services company rather than a growth story, with revenue growth compressed to low single digits by drug-portfolio (CID) headwinds in 2026.
OPCH stock price
As of 2026-07-21, Option Care Health, Inc. (OPCH) last closed at $21.67, down 27.2% over the past year. Over the past 52 weeks it has traded between $19.52 and $36.59.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Option Care Health, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Option Care Health, Inc. (OPCH) do?
Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (like post-hospital antibiotics and nutrition) and chronic conditions (such as immune, neurologic, and inflammatory diseases). It runs a nationwide network of pharmacies and nursing infrastructure, partners with drug manufacturers for distribution, and contracts with payers and health systems, making it the largest standalone player in a fragmented home-infusion market where the top few providers hold roughly a third of share.
The investment picture in 2026 is one of a defensive, cash-generative business working through a soft patch. Revenue is running around $5.7 billion but growing only about 1 percent as acute chronic-inflammatory-drug (CID) portfolio headwinds, including Stelara and biosimilar census resets, drag on the top line. Management has kept its adjusted EBITDA and adjusted EPS guidance intact, and the stock trades at a below-market earnings multiple, so the debate centers on whether the current drug-mix pressure is transitory or a sign of structural reimbursement and competitive risk in a business with thin margins on high drug pass-through revenue.
What's driving Option Care Health, Inc. (OPCH)?
1. Acute infusion demand and hospital partnerships
Acute revenue, covering therapies like anti-infectives and nutrition support delivered after hospital discharge, has been growing at high single digits. As health systems push to move care out of expensive hospital settings, Option Care's national footprint positions it to capture referral volume and consolidate patients, including some exiting CVS Coram's acute business.
2. Margin and cost discipline holding profit targets
Despite a low-single-digit revenue backdrop, management maintained full-year adjusted EBITDA guidance of roughly $480 to $505 million and adjusted EPS of about $1.82 to $1.92, implying mid-single-digit EBITDA and high-single-digit EPS growth at the midpoint. The mix shift toward higher-margin acute work and operating leverage support this even as chronic revenue softens.
3. Cash generation and capital allocation
The company converts earnings into meaningful free cash flow, with trailing levered free cash flow near $170 million and analyst estimates in the $300 million range looking forward. That cash has funded buybacks and tuck-in acquisitions like Intramed Plus, giving management levers to compound per-share value while the top line is muted.
4. Structural tailwind from site-of-care migration
The broader home-infusion market is estimated to grow at a mid-single-digit to low-double-digit rate as payers and patients favor lower-cost home settings over hospitals and clinics. As the scaled independent leader, Option Care is a natural consolidator in a fragmented field of regional and hospital-affiliated providers.
What are the risks to Option Care Health, Inc. (OPCH)?
The most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. Because infusion revenue carries large drug pass-through costs, gross margins are thin and sensitive to reimbursement changes, payer contract terms, and manufacturer distribution economics. Competition from CVS Coram, Optum-affiliated Naven Health, and hospital-owned programs pressures pricing and referral flow. Broader policy risk around drug pricing, Medicare and Medicaid rates, and specialty-pharmacy reimbursement could compress economics. Management framed the census reset as a one-time 2026 event with no 2027 carryover, but if chronic declines persist, growth and the profit guidance could come under renewed pressure.
How is Option Care Health, Inc. (OPCH) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Option Care Health, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$5.7B
- FY2026 revenue guidance: ~$5.68B to $5.78B
- Adjusted EBITDA (FY2026 guide): ~$480M to $505M
- Adjusted EPS (FY2026 guide): ~$1.82 to $1.92
- Market cap: ~$3.4B
- P/E (trailing / forward): ~17x / ~12x
OPCH trades around the low $20s with a market cap near $3.4 billion, a forward P/E in the low teens that sits well below the broader market and many healthcare-services peers. The discount reflects the flat 2026 revenue outlook and drug-mix headwinds rather than a distressed balance sheet, and trailing free cash flow near $170 million underpins the profile.
Who competes with Option Care Health, Inc. (OPCH)?
Payer- and pharmacy-owned infusion arms
CVS Health's Coram and UnitedHealth's Optum-affiliated Naven Health are large, vertically integrated rivals whose payer and pharmacy-benefit ties give them referral and contracting advantages, though Coram's acute exit has also handed share to Option Care.
Infusion product and drug suppliers
Baxter International, Fresenius Kabi, ICU Medical, and B. Braun supply infusion drugs, pumps, and nutrition products; they are partly suppliers and partly competitors in adjacent home and alternate-site delivery, shaping the cost and availability of what Option Care administers.
Regional and hospital-affiliated providers
The home-infusion market is highly fragmented, with numerous regional pharmacies, specialty-pharmacy operators, and hospital-owned outpatient programs competing for local referrals, which is where Option Care's national scale and accreditation are meant to differentiate it.
How to invest in Option Care Health, Inc. (OPCH)
There are three common ways to get OPCH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so OPCH sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where OPCH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Option Care Health, Inc. (OPCH)
Option Care Health is a scaled, profitable infusion-services operator whose near-term revenue is throttled by chronic-drug transitions even as management holds its profit and cash-flow targets.
More on Option Care Health, Inc. (OPCH)
Whether OPCH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OPCH a buy?, and where the stock could go from here in the OPCH stock forecast.
For income investors, whether OPCH pays a dividend and how the payout looks is covered in does OPCH pay a dividend?
Build a basket around OPCH with Walnut
Use Option Care Health, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Option Care Health do?
+
It provides infusion therapy, delivering medications intravenously or by other infusion routes in patients' homes and at alternate-site suites. Its therapies span acute needs like post-hospital antibiotics and nutrition and chronic conditions such as immune, neurologic, and inflammatory diseases.
Is Option Care Health profitable?
+
Yes. It generates positive net income (roughly $200 million on a trailing basis) and meaningful free cash flow, with FY2026 adjusted EBITDA guidance of about $480 to $505 million. Margins are thin because much of its revenue is drug pass-through cost.
Why is OPCH revenue barely growing in 2026?
+
Management cited a roughly 600 basis point headwind from its acute chronic-inflammatory-drug (CID) portfolio, including Stelara and biosimilar census resets and heavier benefit reverification work. Acute therapy is growing high single digits while chronic revenue has declined slightly.
How big is the home infusion market?
+
Industry estimates put the US and global home-infusion market in the tens of billions of dollars, growing at a mid-single-digit to low-double-digit annual rate as care shifts from hospitals to lower-cost home and alternate-site settings.
Who are Option Care Health's main competitors?
+
Key rivals include CVS Health's Coram, UnitedHealth Optum's Naven Health, and numerous regional and hospital-affiliated infusion providers. Baxter, Fresenius Kabi, and ICU Medical are suppliers that also compete in adjacent infusion delivery.
What is OPCH's valuation?
+
As of July 2026 the stock trades around the low $20s with a market cap near $3.4 billion, a trailing P/E around 17x and a forward P/E in the low teens, a discount to the broader market that reflects the muted revenue outlook.
What are the biggest risks for OPCH?
+
Thin margins on drug pass-through revenue, reimbursement and drug-pricing policy changes, payer contract pressure, chronic-drug portfolio transitions, and competition from payer-owned infusion arms are the main risks. Persistent chronic-revenue declines could pressure guidance.
Does Option Care Health pay a dividend?
+
Option Care Health has not been a dividend payer and has instead returned capital primarily through share repurchases while funding tuck-in acquisitions. Always confirm current capital-return policy in the latest company filings before relying on it.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Option Care Health, Inc.'s investor relations page or your broker before making investment decisions.